Systemic Mastocytosis – Pipeline Review, H2 2012

Publisher Name :
Date:31-Oct-2012
No. of pages: 37
Inquire Before Buying

Systemic Mastocytosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Systemic Mastocytosis – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Systemic Mastocytosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Mastocytosis. Systemic Mastocytosis – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Systemic Mastocytosis.
- A review of the Systemic Mastocytosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Systemic Mastocytosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Systemic Mastocytosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Systemic Mastocytosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Systemic Mastocytosis – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Systemic Mastocytosis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Systemic Mastocytosis 7
Systemic Mastocytosis Therapeutics under Development by Companies 9
Systemic Mastocytosis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Systemic Mastocytosis Therapeutics - Products under Development by Companies 14
Systemic Mastocytosis Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Systemic Mastocytosis Therapeutics Development 16
Novartis AG 16
Pharmacyclics, Inc. 17
AB Science 18
Systemic Mastocytosis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
midostaurin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PCI-45261 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
masitinib - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PKC-412 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
thalidomide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Systemic Mastocytosis Therapeutics - Drug Profile Updates 31
Systemic Mastocytosis Therapeutics - Discontinued Products 34
Systemic Mastocytosis Therapeutics - Dormant Products 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products Under Development for Systemic Mastocytosis, H2 2012 7
Products under Development for Systemic Mastocytosis - Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Novartis AG, H2 2012 16
Pharmacyclics, Inc., H2 2012 17
AB Science, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Systemic Mastocytosis Therapeutics - Drug Profile Updates 31
Systemic Mastocytosis Therapeutics - Discontinued Products 34
Systemic Mastocytosis Therapeutics - Dormant Products 35

List of Figures
Number of Products under Development for Systemic Mastocytosis, H2 2012 7
Products under Development for Systemic Mastocytosis - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Chronic Lymphocytic Leukemia (CLL) Treatment Market worth $3.3 billion by 2018
  • New Entrants to Boost Chronic Lymphocytic Leukemia Treatment Market Value to $3.3 Billion by 2018, says GlobalData. The introduction of several new drugs will accelerate growth in the Chronic Lymphocytic Leukemia (CLL) treatment market, from $1.4 billion in 2013 to …

  • Global Biosimilars Market to Grow at a CAGR of 8.3%, to reach $262 billion by 2019
  • Lucrative Biosimilars Space to Erode Biologics Market from 2019, says GlobalData The increasing prevalence of biosimilars will have a noticeably negative impact on the biologics market beyond 2019, despite an initial projected Compound Annual Growth Rate (CAGR) of 8.3%, taking …

  • Saudi Pharmaceutical Market worth $5.9 billion by 2020
  • A high burden of chronic diseases, improving regulatory guidelines and the launch of new products will provide the necessary impetus for the growth of the pharmaceutical market in Saudi Arabia The Saudi pharmaceutical market is one of the largest markets …

  • 2014 Deep Research Report on Global and China Intravenous Catheter Industry
    Published: 22-Jul-2014        Price: US $2200 Onwards        Pages: 184
    This is a professional and depth research report on China Intravenous Catheter industry. The report firstly introduced Intravenous Catheter basic information included Intravenous Catheter definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Intravenous Catheter industry policy and plan, Intravenous Catheter product specification, man......
  • 2014 Deep Research Report on Global and China Particulate Respirators Industry
    Published: 19-Jul-2014        Price: US $2200 Onwards        Pages: 150
    This is a professional and depth research report on Global and China Particulate Respirators industry. The report firstly introduced Particulate Respirators basic information included Particulate Respirators definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis, Particulate Respirators industry policy and plan, Particulate Respirators product specif......
  • 2014 Deep Research Report on Global and China Sialic Acid Industry
    Published: 19-Jul-2014        Price: US $2200 Onwards        Pages: 136
    This is a professional and depth research report on Global and China Sialic Acid industry. The report firstly introduced Sialic Acid basic information included Sialic Acid definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis, Sialic Acid industry policy and plan, Sialic Acid product specification, manufacturing process, cost structure etc. then sta......
  • OpportunityAnalyzer: Dengue Vaccines – Opportunity Analysis and Forecasts to 2020
    Published: 17-Jul-2014        Price: US $5995 Onwards        Pages: 189
    Dengue is a febrile illness caused by the dengue virus (DENV), a single-stranded flavivirus most commonly transmitted by the Aedes aegypti (A. aegypti) mosquito. Thought to be responsible for upwards of 100 million infections each year, DENV is the most prevalent arthropod-borne virus in the world. Individuals infected with DENV can present with a wide spectrum of symptoms, including fevers, retro-orbital pain, severe headache, muscle and joint pain, and rash. The severity of dengue fever ranges......
  • Greece Pharmaceuticals and Healthcare Report Q3 2014
    Published: 16-Jul-2014        Price: US $1295 Onwards        Pages: 116
    BMI View: The Greek pharmaceutical and healthcare sector will continue contract over the medium-tolong term. Although Greece's financial outlook has stabilised and debts are being paid down, the government will continue to target the pharmaceutical and healthcare industry to reduce public spending. We highlight, however, that the generic drug sector and private healthcare industry will present some growth opportunities in the country. Headline Expenditure Projections ? Pharmaceuticals: EUR......
  • Lithuania Pharmaceuticals and Healthcare Report Q3 2014
    Published: 16-Jul-2014        Price: US $1295 Onwards        Pages: 97
    BMI View: We expect the Lithuanian pharmaceutical market to post a five-year compound annual growth rate (CAGR) of 3.8%, rising to a value of LTL2.11bn (USD732mn) in 2018. The upcoming switch to the euro promises to boost purchasing power and stabilise the pharmaceutical market, albeit at the cost of increasing healthcare expenditure. Ceding control of monetary policy to Brussels leaves Lithuania with little leeway to increase its healthcare spending dramatically over the next five years. Th......
  • Moldova Pharmaceuticals and Healthcare Report Q3 2014
    Published: 16-Jul-2014        Price: US $1295 Onwards        Pages: 96
    BMI View: BMI has upgraded its forecast for Moldova's pharmaceutical and healthcare market for 2014 due to improved economic conditions. Moldova is likely to sign the Association Agreement with the EU in June 2014, which would strengthen the business environment and improve the regulatory structure and access to the pharmaceutical market in the country. Moldova is undertaking a reform of its healthcare sector with the World Bank, which is likely to be positive for the sector. Any retaliatory......
  • Serbia Pharmaceuticals and Healthcare Report Q3 2014
    Published: 16-Jul-2014        Price: US $1295 Onwards        Pages: 132
    The new Serbian government is actively trying to stabilise the country's fiscal position through cutting spending, encouraging outside investment and demand pickup for Serbian exports in order to reduce its debt burden. However, pharmaceutical spending is also a target for cuts. Local drug makers are set to feel the worst of these new measures as they cannot compete on cost compared to larger players in the market. The Serbian government has amended the Medicines Act with the specific aim of......
  • Slovakia Pharmaceuticals and Healthcare Report Q3 2014
    Published: 16-Jul-2014        Price: US $1295 Onwards        Pages: 113
    BMI View: The Slovakian government is planning to allocate EUR278mn (USD386.7mn) in EU funding to develop healthcare and medical infrastructure in Slovakia over the 2014-2020 period, reports news agency TASR. The government added that after adding contributions from the state budget, the total funds that have been allocated for developing healthcare infrastructure will be EUR300mn (USD417.3mn). The government plans to allocate these funds to projects in large university hospitals and develop......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs